Integra LifeSciences Holdings Corporation
IARTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeIntegra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and. At a $1.46B market cap, Integra LifeSciences Holdings Corporation ranks as a small-cap company within healthcare. It operates through Codman Specialty Surgical and Tissue Technologies segments.
Market Cap
$1.46B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
7.17
EPS (TTM)
$-6.60
EPS (Fwd)
$2.62
ROE
-38.6%
ROA
2.5%
Cash
$265.5M
Total Debt
$2.04B
Free CF
$69.3M
52W Change
55.2%
Annual Financials
Cash vs Debt
On the balance sheet, IART has $265.5M in cash with $2.04B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $69.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -38.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.56B (2022) to $1.64B (2025).
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IART.